Compare General Mills, Inc. (GIS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Novo Nordisk A/S — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 9.5× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Novo Nordisk A/S for 116 Days on average.
| GIS | NVO | |
|---|---|---|
Market Cap | $17.43B | $165.31B |
Volume | 16,554,362 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $63.98 |
52-Week Low | $31.67 | $35.29 |
Typical Hold Time | 106 Days | 116 Days |
Enterprise Value | $30.61B | $179.56B |
Dividend Yield | 7.49% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, amid a bearish technical outlook. The stock shows mixed fundamentals with a low P/E of 9.23 and a dividend yield supported by a $0.61 quarterly payout, but profitability metrics like a negative net income margin and ROE highlight challenges. Recent Q1 2027 earnings beat expectations, yet revenue trends are declining, and a CEO transition adds uncertainty. Analyst consensus is cautious with a $36.00 price target and a majority hold rating.
The outlook remains guarded due to margin pressures and competitive headwinds, though the dividend offers income appeal. Risks include potential earnings volatility and high debt levels. Upside depends on successful execution of cost-saving initiatives and volume recovery, but near-term performance may be constrained by macroeconomic factors.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
